OBIO is proud to announce a national call for applications from health science companies, seeking Series A and beyond investments, to present at the 2019 Niagara Investment Summit, February 20-22, 2019.
The Ontario Bioscience Innovation Organization (OBIO®) is honoured to announce the conclusion of the successful Canadian Health Investment Showcase which took place in New York, NY, on November 5 and 6, 2018.
The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce the opening of the Canadian Health Investment Showcase in New York, NY, on November 5 and 6, 2018.
The Canadian Health Investment Showcase will feature 18 of Canada’s highest potential companies meeting with more than 35 US investors and VCs in New York City to drive investment in Canada’s health science industry.
Over two days at the Consulate General of Canada in New York, the Canadian Health Investment Showcase features hundreds of one-on-one meetings between companies and US investors, as well as panel discussions on cross-border investing in the health science industry and a keynote on trends in health investing this year.
To find out more, click here to read the full press release.
OBIO is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 11 high-potential health companies in this year’s cohort. Now in its sixth year, this year’s OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives which will position them for successful financing.
The Ontario Bioscience Innovation Organization (OBIO®) released its latest report, ‘Use It or Lose It: Industry Solutions to Ontario’s Commercialization Gap’, with recommendations from health science company executives on how to create the conditions for the growth of Ontario’s health science industry.
Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit membership based organization that is Ontario’s leading advocate for the health science industry, announced today that Ontario health science companies that have participated in its Capital Access Advisory Program (CAAP®) have raised more than $109 Million since the CAAP program launched in 2013.
January 24, 2017 TORONTO--(BUSINESS WIRE)--The Ontario Bioscience Innovation Organization (OBIO®) hosted a summit of industry, academic, government and investment leaders about the future of health science innovation in Canada. Attendees engaged in group discussions and heard from subject matter experts to extrapolate a mandate of action for anchoring health science companies in Ontario. The outcome of the summit lays a foundation for actionable business cases for private and public sector solutions to the health science industry’s biggest challenges: Innovation Pull, Adoption and Capital Attraction.
Versant Ventures has announced the close of its newest fund, Versant Venture Capital VI, at its hard cap of CAD538 million (USD400 million). Versant will use its diversified global investment strategy to find, form and fund innovative healthcare companies with an emphasis on novel therapeutics.
TORONTO, Dec. 7, 2016 - HOWE&WYE is proud to announce its new partnership with OBIO®. As a part of OBIO's new member benefit, HOWE&WYE will provide strategic public relations and communications services to OBIO's broad membership of world-class start-ups and bioscience companies. OBIO members will benefit from special access to top-tier agency support with optimized pricing to strengthen PR and marketing to fulfill strategic business outcomes for awareness, investment and commercialization.
Toronto, Ontario, December 6, 2016 – Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit, membership based organization, that is Ontario’s leading advocate for the health science industry, hosted its Annual Public Meeting with the theme centered on “Bridging the Access to Talent Gap” at Norton Rose Fulbright LLP yesterday. The OBIO Annual Public Meeting provided a platform to highlight OBIO’s accomplishments made in 2016, upcoming initiatives for 2017 and an opportunity to hear from Parliamentary Assistant to the Minister of Economic Development and Growth, Cristina Martins and Members of the OBIO MPP Health Science Caucus, MPP Shafiq Qaadri and MPP Bill Walker, who welcomed networking with over 60 health science industry professionals.
The evening focused on a vision of collaboration across health science companies and highlighted the supportive partnership that the Province of Ontario has with OBIO. The evening also marked the launch of the OBIO Health to Business Bridge™ H2BB™ internship program. OBIO H2BB™ is a program in support of improving access to business trained talent in Ontario’s health science sector, ultimately contributing to a sustainable innovation economy.
The H2BB™ internship program will combine OBIO’s deep-rooted relationships across academia and industry to develop industry ready talent that strengthens business development capabilities in Ontario’s health science companies, and ultimately amplifies the innovation capability of the province.
OBIO H2BB™ provides companies with a unique opportunity to access new talent, while assisting with critical business projects. Interns will rapidly develop knowledge and insight into new and ultimately profitable technologies.
Participation in OBIO H2BB™ is open to all Ontario companies developing health science products or services, who are interested in hiring a business trained intern to help complete a managerial project for a minimum duration of four-months. Interested companies are encouraged to contact OBIO to discuss their interest.
The Ontario Bioscience Innovation Organization (OBIO®) is a not-for-profit, membership-based organization engaged in the development of an integrated health innovation economy for Ontario and one that will become a global leader in providing health technology products and services to the international marketplace. OBIO advances this goal through advocacy, promotion and strategic leadership and via collaborative partnerships with industry, academia, patients and government.
For more information, visit the OBIO website www.obio.ca and follow OBIO on Twitter @OBIOscience.
Program Manager, Health to Business Bridge
416-848-6839 ext. 107
President and Chief Executive Officer, OBIO
416-848-6839 ext. 101